Sudarshan Jain Archives - Express Pharma

A biosimilar boost amid trade barriers

Industry experts respond to FDA move to streamline biosimilar development

India invites proposals under PRIP scheme to propel Pharma‑MedTech R&D projects

Session 14 of FOPE & PharmaState Academy’s PULSE Program explores investigations & CAPA under Revised Schedule M

US tariffs leave Indian pharma unaffected, industry voices relief

Panel Discussion: The patient of the future: Shaping pharma’s next big opportunity

Balancing MAGA and MIGA

Dealsphere launches in India, streamlining nutraceutical licensing and commercialisation

Trumping the Budget blues?

Exemptions, concessional duty on essential medicines to improve drug access: Sudarshan Jain, IPA